Q-omics provides the consensus-scored SERTAD4-AS1 profile across patient tissues and cancer cell-line models. SERTAD4-AS1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, SERTAD4-AS1 is differentially expressed in 13, with the highest sampling consensus in UCEC. Additionally, SERTAD4-AS1 RNA expression shows 15,646 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight OV, UCEC, and TGCT as cancer lineages where SERTAD4-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERTAD4-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERTAD4-AS1 survival associations across molecular data types. SERTAD4-AS1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERTAD4-AS1 RNA expression–survival associations across cancer types. High SERTAD4-AS1 expression shows unfavorable associations in LGG, but favorable associations in OV, KIRP, ACC, THYM and UCEC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for SERTAD4-AS1 RNA expression.
This table summarizes SERTAD4-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for SERTAD4-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERTAD4-AS1 shows lower tumor expression in UCEC, LUSC, COAD, BRCA and LUAD and higher tumor expression in LIHC. The UCEC box plot shows higher SERTAD4-AS1 RNA expression in normal versus tumor tissue (log2 FC = −3.240, t-test p < 0.001).
This table shows molecular features associated with SERTAD4-AS1 in patient tissues and cancer cell lines. In patient samples, SERTAD4-AS1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
